Retinal delivery platforms for blinding disease

Unlocking gene and protein delivery to the retina through office‑based ocular routes.

Visiogene is advancing AAV‑IKV gene delivery and Nuc1 protein delivery technologies designed to reach retinal cells that are difficult to access with conventional approaches.

View pipeline Explore the platform
2delivery modalities
3+ocular disease models
Peer‑reviewedpreclinical foundation
AAV‑IKVNuc1
Intravitreal retinal accessDesigned for delivery to outer retinal targets including photoreceptors and RPE.

Visiogene is building a pipeline around proprietary delivery technologies for retinal degeneration, including age‑related macular degeneration and glaucoma.

See the pipeline

Platform strategy

Two complementary platforms. One retinal delivery thesis.

AAV‑IKV and Nuc1 are designed to expand the range of therapeutic payloads that can reach ocular targets while preserving routes familiar to ophthalmology practice.

Gene delivery

AAV‑IKV retinal penetrating vector

A capsid platform engineered to deliver transgenes to ocular tissues following intravitreal or intracameral administration in preclinical studies.

  • Outer retina delivery including photoreceptors and RPE in mice
  • Anterior segment delivery including trabecular meshwork in preclinical glaucoma studies
  • Payload optionality for disease-modifying transgenes
Protein delivery

Nuc1 cell‑penetrating chaperone

A delivery-enabling peptide designed to move small and large molecules into retinal cells without chemical conjugation to the cargo.

  • Supports recombinant proteins, antibodies, peptides, and viral vectors
  • Designed for co‑administration and retinal cell uptake
  • Potential to expand biologics and combination strategies

Company thesis

A delivery-led ocular therapeutics company.

Visiogene pairs a platform capable of addressing known delivery bottlenecks with programs where local, durable expression could reshape treatment frequency, biologic reach, and disease modification.

01

Differentiated administration route

AAV‑IKV is designed to reduce reliance on surgically created subretinal access for outer retinal targets and to enable anterior segment gene delivery for glaucoma biology.

02

Multifunctional biology in wet AMD and glaucoma

Decorin is positioned against fibrosis and TGFβ‑driven disease biology, with additional relevance to neovascularization, inflammation, and autophagy.

03

Platform read‑through

Each program tests both the delivery layer and a therapeutic payload, creating opportunities for indication expansion and partnering.

Programs

Focused ocular pipeline with multiple value‑creation paths.

Lead retinal program

Wet AMD: AAV‑IKV‑Decorin

Designed to deliver human decorin to the outer retina through intravitreal administration, with preclinical activity against CNV and fibrosis.

Learn more →
Anterior segment

Glaucoma: AAV‑IKV‑Decorin

Targeting the TGFβ2 / decorin axis and trabecular meshwork fibrosis to address elevated intraocular pressure biology.

Learn more →
Discovery

Dry AMD: undisclosed complement-targeted treatment

Undisclosed local complement-modulation program designed to build on founder experience in complement-targeted ocular gene therapy.

Learn more →
Discovery

Undisclosed retinal degeneration treatment

A second undisclosed retinal degeneration program designed to extend Visiogene’s delivery platform across inherited and acquired retinal disease biology.

Learn more →
Platform expansion

Nuc1-enabled biologics

Protein and large-molecule delivery programs enabled by intracellular retinal delivery without chemical conjugation.

Learn more →

Leadership

Founded by ocular gene therapy experience.

Rajendra Kumar‑Singh, PhD

Founder and President

Professor at Tufts University School of Medicine and scientific founder of Hemera Biosciences. Prior work includes the soluble sCD59 program for dry AMD, later acquired by Janssen Pharmaceuticals.

Contact

Partnering and strategic discussions for a retinal delivery platform company.

For company information, partnering discussions, or scientific collaborations, contact Visiogene.

Start a conversation